Wednesday, April 05, 2017 2:15:37 AM
Oxis International Inc. Announces Approval of FDA Phase 2 Trial with Its Bispecific Antibody OXS-1550
https://finance.yahoo.com/news/oxis-international-inc-announces-approval-123000457.html
relies on highly expensive autologous cell therapies such as presented by Kite Pharma, Inc. (KITE), Juno Therapeutics, Inc. (JUNO)
FYI: Its competitors are KITE, JUNO
Guess What ?
JUNO = $23. per share.
KITE= $75.90 per share.
Dr. Daniel Vallera, director of the section on Molecular Cancer Therapeutics at the University of Minnesota Cancer Center, lead developer of OXS-1550 said, "The FDA's clearance for Phase 2 is an important step forward for this cancer treatment."
Dr. Vallera has spent 35 years with the University of Minnesota's cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.
"We are excited to see this new therapy proceed to Phase 2," Dr. Vallera said. "So many of these patients presenting with chemotherapy refractory cancer have few, if any, alternative choices for cancer treatment."
OXIS= Strong BUY.
$$$$$$$$$$ Go OXIS $$$$$$$$
Recent GTBP News
- The $13 Million Company Teaching the Immune System to Hunt Cancer • PR Newswire (Canada) • 05/29/2026 01:00:00 PM
- The $13 Million Company Teaching the Immune System to Hunt Cancer • PR Newswire (US) • 05/29/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:00:37 PM
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes • PR Newswire (Canada) • 05/19/2026 01:00:00 PM
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes • PR Newswire (US) • 05/19/2026 01:00:00 PM
- B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic • PR Newswire (Canada) • 05/18/2026 06:22:00 PM
- B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic • PR Newswire (US) • 05/18/2026 06:22:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 12:00:50 PM
- "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies • GlobeNewswire Inc. • 05/14/2026 02:55:00 PM
- A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology • GlobeNewswire Inc. • 05/14/2026 01:15:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/14/2026 04:15:35 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/13/2026 09:18:43 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/30/2026 08:55:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 11:05:14 AM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 03/06/2026 09:01:09 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 03/06/2026 09:01:05 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 12:05:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 12:05:27 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/30/2026 10:12:20 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/21/2026 09:15:32 PM
- 5 Assets Securing the 2026 Material Cycle • GlobeNewswire Inc. • 01/16/2026 04:18:58 PM
- Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape • PR Newswire (US) • 01/16/2026 01:00:00 PM
- Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape • PR Newswire (Canada) • 01/16/2026 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/08/2026 09:19:06 PM
